Clay TM - Search Results

1

Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.

Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, Morse MA, Clay TM, Lyerly HK, Bhatia S, Ghanekar SA, Maino VC, Delarosa C, Disis ML. Maecker HT, et al. Among authors: clay tm. BMC Immunol. 2008 Mar 17;9:9. doi: 10.1186/1471-2172-9-9. BMC Immunol. 2008. PMID: 18366814 Free PMC article.

2

Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT.

Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang JC, Summers A, Clay TM, Morse MA, Lyerly HK, DeLaRosa C, Ankerst DP, Disis ML. Maecker HT, et al. Among authors: clay tm. BMC Immunol. 2005 Jul 18;6:17. doi: 10.1186/1471-2172-6-17. BMC Immunol. 2005. PMID: 16026627 Free PMC article.

3

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM. Hobeika AC, et al. Among authors: clay tm. J Immunother. 2005 Jan-Feb;28(1):63-72. doi: 10.1097/00002371-200501000-00008. J Immunother. 2005. PMID: 15614046

4

Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Hobeika AC, et al. Among authors: clay tm. Crit Rev Immunol. 2001;21(1-3):287-97. Crit Rev Immunol. 2001. PMID: 11642610 Review.

5

Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.

Osada T, Morse MA, Lyerly HK, Clay TM. Osada T, et al. Among authors: clay tm. Int Immunol. 2005 Sep;17(9):1143-55. doi: 10.1093/intimm/dxh292. Epub 2005 Jul 18. Int Immunol. 2005. PMID: 16027139

6

Preparation of peptide-loaded dendritic cells for cancer immunotherapy.

Morse MA, Clay T, Colling K, Lyerly HK. Morse MA, et al. Mol Biotechnol. 2003 Sep;25(1):95-9. doi: 10.1385/MB:25:1:95. Mol Biotechnol. 2003. PMID: 13679640

7

Dendritic cell-based immunotherapy.

Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK. Osada T, et al. Among authors: clay tm. Int Rev Immunol. 2006 Sep-Dec;25(5-6):377-413. doi: 10.1080/08830180600992456. Int Rev Immunol. 2006. PMID: 17169781 Review.

8

Maximizing the retention of antigen specific lymphocyte function after cryopreservation.

Disis ML, dela Rosa C, Goodell V, Kuan LY, Chang JC, Kuus-Reichel K, Clay TM, Kim Lyerly H, Bhatia S, Ghanekar SA, Maino VC, Maecker HT. Disis ML, et al. Among authors: clay tm. J Immunol Methods. 2006 Jan 20;308(1-2):13-8. doi: 10.1016/j.jim.2005.09.011. Epub 2005 Oct 21. J Immunol Methods. 2006. PMID: 16337957

9

Surrogate markers of response to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Morse MA, et al. Among authors: clay tm. Expert Opin Biol Ther. 2001 Mar;1(2):153-8. doi: 10.1517/14712598.1.2.153. Expert Opin Biol Ther. 2001. PMID: 11727526

10

NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.

Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. Osada T, et al. Cancer Immunol Immunother. 2006 Sep;55(9):1122-31. doi: 10.1007/s00262-005-0089-3. Epub 2005 Nov 5. Cancer Immunol Immunother. 2006. PMID: 16273350 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

118 results

Search Page